Mild Cognitive Impairment - Market Insight, Epidemiology And Market Forecast - 2034

Mild Cognitive Impairment - Market Insight, Epidemiology And Market Forecast - 2034

Key Highlights

The Parainfluenza virus infection market is projected to witness consistent growth throughout the forecast period (2024–2034). The market size of parainfluenza virus infection in the 7MM is expected to increase, driven by increasing Incident population.

DelveInsight’s analyst projects that the total Incident Cases of Parainfluenza Virus in 7MM were approximately 2,709,923 in 2023 and these cases are further expected to increase during the forecasted period (2024–2034).

Most number of Incident cases were estimated in the US, followed by Japan, Spain, and Germany in 2023.

In the 7MM, the market mainly consisted of standard of care, which generated nearly USD 259 million in 2023.

The total size of the parainfluenza virus infection treatment market is anticipated to experience growth during the forecast period due to the increase in incident population of PIV Infection.

DelveInsight’s “Parainfluenza Virus Infection– Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the Parainfluenza Virus Infection, historical and forecasted epidemiology and the Parainfluenza Virus Infection market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Parainfluenza Virus Infection market report provides current treatment practices, market share of individual therapies, and current and forecasted 7MM, Parainfluenza Virus Infection market size from 2020 to 2034. The report also covers current Parainfluenza Virus Infection treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2020–2034

Disease Understanding and Treatment Algorithm

Parainfluenza Virus Infection Overview

Parainfluenza virus (PIV) infection is a respiratory illness caused by one of four types of parainfluenza viruses: PIV-1, PIV-2, PIV-3, and PIV-4. These viruses belong to the Paramyxoviridae family and primarily affect the respiratory tract, leading to various respiratory infections such as the common cold, croup, bronchiolitis, and pneumonia.

The causes of PIV infection involve transmission through respiratory droplets expelled when an infected person coughs, sneezes, or talks. Additionally, indirect transmission can occur through contact with contaminated surfaces.

Symptoms of PIV infection vary depending on the type and severity of the illness but commonly include symptoms of the common cold such as runny nose, cough, sore throat, and fever. In more severe cases, symptoms may include difficulty breathing, wheezing, and chest pain.

Parainfluenza Virus Infection Diagnosis

Diagnosis of PIV infection involves clinical evaluation, including a review of symptoms and medical history, as well as laboratory tests such as PCR or antigen detection tests on respiratory specimens. These tests can detect the presence of parainfluenza virus genetic material or antigens. Differential diagnosis may be necessary to distinguish PIV infection from other respiratory viruses with similar symptoms.

Further details related to country-based variations are provided in the report

Parainfluenza virus infection Treatment

Treatment for PIV infection is primarily supportive and focuses on relieving symptoms. This may include rest, adequate hydration, fever-reducing medications, and humidified air to alleviate respiratory symptoms. In severe cases, especially in immunocompromised individuals, antiviral medications such as ribavirin may be considered. However, their efficacy is uncertain, and they are not routinely recommended.

Parainfluenza virus infection Epidemiology

As the market is derived using the patient-based model, the Parainfluenza virus infection epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Parainfluenza virus infection, Serotype-specific Incident Cases of Parainfluenza Virus, Gender-specific Incident Cases of Parainfluenza Virus, and Age-specific Incident Cases of Parainfluenza Virus in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.

According to DelveInsight estimations, 2,709,923 Cases of Parainfluenza virus infection were found in 2023 in the 7MM.

As per DelveInsight’s estimations, the total number of incident cases of parainfluenza virus in the United States were 1,456,399 in 2023 and are projected to increase during the forecast period.

According to DelveInsight’s estimates, the total Incident Cases of parainfluenza virus infection in EU4 and the UK were found to be 991,115 in 2023. The highest proportion of parainfluenza virus infection cases was reported in Spain among the EU4 countries, while the least number of cases was found in the UK.

The estimates show the number of parainfluenza virus infection cases in Japan was found to be approximately 262,409 in 2023, which is estimated to increase by 2034.

Parainfluenza Virus Infection Drug Chapters

The drug chapter segment of the Parainfluenza Virus Infection report encloses a detailed analysis of Parainfluenza Virus Infection marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also understands Parainfluenza Virus Infection clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Drugs

DAS181: Ansun Biopharma

DAS181 is a first-in-class recombinant sialidase protein that is designed to remove sialic acids located on the surface of epithelial cells lining the human respiratory tract. These sialic acids are naturally present on cell surfaces and are needed by some viruses for viral entry into cells. Cleavage of sialic acid inactivates the mechanism for viral entry and infection, interrupting the virus lifecycle and giving patients the chance to recover.

DAS181 has demonstrated antiviral activity against three of the four major respiratory viruses, influenza virus (IFV), parainfluenza virus (PIV), and metapneumovirus (MPV), as well as human enterovirus-68 (EV-68).

ALVR106: AlloVir

ALVR106 is an allogeneic, off-the-shelf, multivirus-specific VST investigational therapy designed to target infections and diseases caused by the respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). In vitro data demonstrate that ALVR106 has antiviral activity against each of the targeted viruses with minimal or no activity against non-virus-infected cells. (AlloVir, 2024).

It is being developed in Phase I/II of clinical trials as per the company’s pipeline; however, the trial evaluating it was terminated before its completion as part of a strategic sponsor decision. The preclinical data of ALVR106 supports the potential for antiviral benefit and safety of ALVR106 when administered to patients.

Note: Detailed emerging therapies assessment will be provided in the final report of Parainfluenza Virus Infection

Parainfluenza Virus Infection Market Outlook

Presently, the primary approach to treating HPIV infection involves supportive care, except for croup, where corticosteroids have been identified as beneficial. Novel drugs like DAS181 show promise for treating severe cases in immunocompromised patients and are currently undergoing development.

Despite continuous endeavors, effective treatment options for PIV infection remain lacking, with no approved medications addressing this critical gap in care. Specifically, there is still no FDA-approved cure or antiviral medication designated for treating HPIV infection.

Most cases of PIV infections tend to resolve without requiring targeted medical treatment. Nonetheless, supportive strategies such as adequate rest, hydration, and the use of over-the-counter medications to relieve symptoms may be recommended. In severe cases or among individuals with weakened immune systems, antiviral medications or hospitalization may be necessary. Additionally, Ribavirin is sometimes administered off-label for treating PIV infections due to its in vitro activity. However, its effectiveness is subject to debate, as there is a lack of data from randomized trials.

The market for Parainfluenza Virus Infection is expected to experience positive growth.

The total market size of Parainfluenza Virus Infection in the 7MM was around USD 259 million in 2023. This is estimated to increase by 2034 at a significant CAGR.

Among the 7MM, the US captured the highest market in 2023, covering a total of 68% market, followed by EU4 and the UK, which is anticipated to grow during the forecast period (2024–2034).

In 2023, EU4 and the UK captured nearly 23% of the total market in the 7MM.

Japan secured the second largest market share across all 7MM, and it is anticipated to increase by 2034.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Parainfluenza Virus Infection evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Department of Emergency Medicine, State University of New York at Stony Brook Health Sciences Center, US, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, US, Comprehensive Heart Failure Centre Würzburg and Department of Internal Medicine, University and University Hospital Würzburg, Germany, Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan and others.

DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or Parainfluenza Virus Infection market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst’s discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Market Access and Reimbursement

The high cost of therapies for the treatment is a major factor restraining the growth of the drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.

The report further provides detailed insights on the country accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report

The report covers a segment of key events, an executive summary, descriptive overview of Parainfluenza Virus Infection, explaining its causes, signs and symptoms, and currently available therapies.

Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.

Additionally, a comprehensive overview of existing therapies, along with an analysis of how the introduction of generic drugs will impact the current treatment landscape.

A detailed review of the Parainfluenza Virus Infection market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.

The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preference that help shape and drive the 7MM Parainfluenza Virus Infection market.

Parainfluenza Virus Infection Report Insights

Patient Population

Therapeutic Approaches

Parainfluenza Virus Infection Market Size and Trends

Existing and Future Market Opportunity

Parainfluenza Virus Infection Report Key Strengths

11 years Forecast

The 7MM Coverage

Parainfluenza Virus Infection Epidemiology Segmentation

Drugs Uptake and Key Market Forecast Assumptions

Parainfluenza Virus Infection Report Assessment

Current Treatment Practices

Unmet Needs

Market Attractiveness

Qualitative Analysis (SWOT Analysis)

Key Questions

Market Insights

What was the Parainfluenza Virus Infection total market size, the market size by therapies, and market share (%) distribution in 2020, and how would it all look in 2034? What are the contributing factors for this growth?

What unmet needs are associated with the current treatment market of Parainfluenza Virus Infection?

Which drug is going to be the largest contributor by 2034?

What are the pricing variations among different geographies for off-label therapies?

How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights

What are the disease risk, burdens, and unmet needs of Parainfluenza Virus Infection? What will be the growth opportunities across the 7MM concerning the patient population of Parainfluenza Virus Infection?

What is the historical and forecasted Parainfluenza Virus Infection patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?

What factors are affecting the diagnosis of the indication?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

What are the current options for treating Parainfluenza Virus Infection? What are the current guidelines for treating Parainfluenza Virus Infection in the US and Europe?

How many companies are developing therapies for Parainfluenza Virus Infection?

How many emerging therapies are in the mid-stage and late stage of development Parainfluenza Virus Infection?

What are the key designations that have been granted for the emerging therapies for Parainfluenza Virus Infection?

What is the cost burden of approved therapies on the patient?

Patient acceptability in terms of preferred treatment options as per real-world scenarios?

What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.

What are the 7MM historical and forecasted markets of Parainfluenza Virus Infection?

Reasons to Buy

The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the parainfluenza virus infection Market.

Insights on patient burden/disease Incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

To understand the existing market opportunity in varying geographies and the growth potential over the coming years.

Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.

Detailed analysis, ranking of class-wise potential current, and emerging therapies under the conjoint analysis section to provide visibility around leading classes.

Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.

To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.

Detailed insights on the unmet need of the existing market so that the upcoming players can strengthen their development and launch strategy.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Parainfluenza virus infection Epidemiology and Market Insight report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of market dynamics and trends during this timeframe.

2. How is the market size estimated in the forecast report?

The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as Incident cases, treatment costs; revenue generated, and market trends.

3. What is the key driver of the parainfluenza virus infection market?

The increasing incident population and emerging drugs are attributed to be the key driver for increasing parainfluenza virus infection market.

4. What is the expected impact of emerging therapies or advancements in parainfluenza virus infection treatment on the market?

Introducing new therapies, advancements in disease understanding and diagnostic techniques, and innovations in treatment approaches can significantly affect the parainfluenza virus infection treatment market. Market forecast reports might provide analysis and predictions regarding the potential impact of these developments.

5. Does the report provide insights into the competitive landscape of the market?

The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the parainfluenza virus infection market.